Clinical Trial Update: Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination [Phase 3]

View source ↗

Summary

A Phase 3 endometrial safety study evaluating a fixed-dose combination of 0.5 mg estradiol and 2.5 mg dydrogesterone in postmenopausal women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopause

Drugs mentioned

• Dydrogesterone (dydrogesterone)
• ESTRADIOL (Estradiol)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Postmenopause | Phase 3 | Status: COMPLETED